Arena Pharma FADES Below $10 and 4 High Demand Stocks ATTRACTING Eyes

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Bristol Myers Squibb Co. (NYSE:BMY) and Astra-Zeneca (NYSE:AZN) are the most logical suitors for Amylin, thinks Tim Anderson at Bernstein, but he does not expect that such a purchase would significantly change the financial outlook for either firm. Shares of Bristol Myers Squibb Co. are trading 0.17% lower today.

Don’t Miss: Here are the STUDS and DUDS of the DOW for 2012.

Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) reports that it is going forward with a development plan for a combination medication for the treatment of both premature ejaculation, or PE, and erectile dysfunction. The firm received clear guidance at the positive pre-IND meeting in June with the FDA, for the two concurrent pivotal trials required for approval of Zertane to treat PE in the U.S. Shares of Ampio Pharmaceuticals, Inc. are trading 13.78% higher today.

Amarin Corporation plc (NASDAQ:AMRN) says that the United States Patent and Trademark Office has published its notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/769,885 titled “Highly Stable EPA in a Capsule”, which would cover a stable pharmaceutical composition of AMR101 that comprises at minimum 95 percent EPA and would also have a patent term with expiration no earlier than 2030. Shares of Amarin Corporation plc are trading 3.46% higher today.

ATP Oil & Gas Corporation (NASDAQ:ATPG) reports that the Shimson well in the Mediterranean off the coast of Israel hit more than 62 feet of natural gas pay. The bore is at a water depth of 3,622 feet and was drilled to a subsea depth of 14,445 feet. ATPG owns 40 percent of the discovery, and expects to provide additional information about the discovery during the third quarter. Shares of ATP Oil & Gas Corporation are trading 18.45% higher today.

Arena Pharmaceuticals (NASDAQ:ARNA) pushed through the first new diet drug in 13 years when it received the FDA’s approval of Lorcaserin, but investors have since taken a second look and have sold many shares they bought during the euphoria last week. Monday, shares are once again below the $10 mark. Shares of Arena Pharmaceuticals are trading 3.26% lower today.

Don’t Miss: Will Google Come Through for Nokia Where Microsoft FAILED?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business